Search This Blog

Sunday, June 21, 2026

MoonLake positive Week 52 Phase 3 in hidradenitis suppurativa, plans BLA submission by September

 

MoonLake reports positive Week 52 Phase 3 VELA results for sonelokimab in hidradenitis suppurativa, plans FDA BLA submission by September 2026

  • Week 52 VELA data showed strong efficacy of sonelokimab in hidradenitis suppurativa with no new safety signals reported.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)